FMT in Cirrhosis and Hepatic Encephalopathy
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Richmond, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 60 people enrolled
- Started
- 29 Jul 2019
- Ended
- 20 Dec 2023
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Fecal Microbial transplant Capsules
- Fecal Microbial Transplant Enema
- Placebo
- Record updated
- 25 May 2025
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Cirrhosis diagnosed by either of the following in a patient with chronic liver disease; Liver Biopsy; Radiologic evidence of varices, cirrhosis or portal hypertension; Laboratory evidence of platelet count <100,000 or AST/ALT ratio>1; Endoscopic evidence of varices or portal gastropathy; Fibroscan values suggestive of cirrhosis
- On treatment for hepatic encephalopathy (patient can be on lactulose and rifaximin)
- Able to give written, informed consent (demonstrated by mini-mental status exam>25 at the time of consenting)
- Women of child bearing potential must agree to use effective contraception for the duration of the study and for 10 days prior and 30 days after the study
- Negative pregnancy test in women of childbearing age
Who cannot take part
- Currently on antibiotics apart from rifaximin
- Patients on renal replacement therapy
- Major gastro-intestinal or intra-abdominal surgery in the last three months; Other Exclusion Criteria:
- Infection at the time of the FMT (diagnosed by blood culture positivity, urinalysis, paracentesis as needed)
- Patients with untreated, in-situ colorectal cancer
- Patients with a history of chronic intrinsic GI diseases such as inflammatory bowel disease; ulcerative colitis, Crohn's disease or microscopic colitis; eosinophilic gastroenteritis or celiac disease
- WBC count <1000 cells/mm3
- Platelet count<25,000/mm3
- Patients who are immuno-compromised due to the following reasons:; HIV infection (any CD4 count); Inherited/primary immune disorders; Current or recent (<3 mos) treatment with anti-neoplastic agent; Current or recent (<3 mos) treatment with any immunosuppressant medications [including but not limited to monoclonal antibodies to B and T cells, anti-TNF agents, glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine), calcineurin inhibitors (tacrolimus, cyclosporine), mycophenolate mofetil]; Subjects who are otherwise immunocompetent and have discontinued any immunosuppressant medications 3 or more months prior to enrollment may be eligible to enroll
- Enema-related; Platelet count<25,000; Grade IV hemorrhoids
- Safety-related:; Dysphagia; History of aspiration, gastroparesis, intestinal obstruction; Ongoing antibiotic use (except for Rifaximin); Severe anaphylactic food allergy; Allergy to ingredients Generally Recognized As Safe in the FMT capsules (glycerol, sodium chloride, hypromellose, gellan gum, titanium dioxide, theobroma oil); Adverse event attributable to prior FMT; ASA Class IV or V; Pregnant or nursing patients; Acute illness or fever within 48 hours of the day of planned FMT; Immunocompromised due to medical conditions; Probiotics use within the last 48 hours of the day of planned FMT; Any condition that the physician investigators deem unsafe, including other conditions or medications that the investigator determines puts the participant at greater risk from FMT
- MELD score >22
- TIPS in place for less than a month
- Hospitalization for any non-elective cause within the last 1 month
- Patients who are pregnant or nursing (will be checked using a urine pregnancy test)
- Patients who are incarcerated
- Patients who are incapable of giving their own informed consent
Where in United States
- Hunter Holmes McGuire VA Medical Center, Richmond, VARichmond, United States
About the trial
What the trial wants to find out
Patients with end stage of liver disease or cirrhosis can develop confusion due to high ammonia and inflammation. This confusion is brought upon by changes in the bacteria in the bowels and may not respond to current standard of care treatments. Repeated episodes of confusion can make it difficult for patients to function and may result in multiple admissions to the hospital and burden on the family. The investigators have studied using a healthy person's stool to replace the bowel bacteria, called fecal microbial transplant, in small studies with good results. In this trial the investigators propose to perform these procedures using an upper and lower route in Veterans who suffer from this condition and follow them for safety and HE and related hospitalizations over 6 months. The investigators will compare this to placebo treatments and hope that this intervention can improve the health and daily functioning of affected patients.
The 4 groups in the trial
- PlaceboPlacebo, for comparison
Oral and rectal placebo at visit 2 Oral placebo at day 30
- Group 3: Oral placebo and rectal FMTExisting treatment, for comparison
Oral placebo and rectal FMT at visit 2 Oral placebo at day 30
Treatment: Fecal Microbial Transplant Enema and Placebo
- Group 2: Oral FMT and rectal placeboExisting treatment, for comparison
Oral FMT and rectal placebo at visit 2 Oral FMT at day 30
Treatment: Fecal Microbial transplant Capsules
- Group 1: Dual Oral and rectal FMTTreatment being tested
Dual Oral and rectal FMT at visit 2 Oral FMT at day 30
Treatment: Fecal Microbial transplant Capsules and Fecal Microbial Transplant Enema
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Fecal Microbiota Transplant in Veterans With Cirrhosis
- Publications
- The multi-omic basis for hepatic encephalopathy recurrence: Analysis of the THEMATIC trial.JHEP reports : innovation in hepatology, 2026
- A critical review of microbiome-derived metabolic functions and translational research in liver diseases.Frontiers in cellular and infection microbiology, 2025
- Record updated
- 25 May 2025